<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37809081</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2 spike antigen-specific B cell and antibody responses in pre-vaccination period COVID-19 convalescent males and females with or without post-covid condition.</ArticleTitle><Pagination><StartPage>1223936</StartPage><MedlinePgn>1223936</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1223936</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1223936</ELocationID><Abstract><AbstractText Label="BACKGROUND">Following SARS-CoV-2 infection a significant proportion of convalescent individuals develop the post-COVID condition (PCC) that is characterized by wide spectrum of symptoms encompassing various organs. Even though the underlying pathophysiology of PCC is not known, detection of viral transcripts and antigens in tissues other than lungs raise the possibility that PCC may be a consequence of aberrant immune response to the viral antigens. To test this hypothesis, we evaluated B cell and antibody responses to the SARS-CoV-2 antigens in PCC patients who experienced mild COVID-19 disease during the pre-vaccination period of COVID-19 pandemic.</AbstractText><AbstractText Label="METHODS">The study subjects included unvaccinated male and female subjects who developed PCC or not (No-PCC) after clearing RT-PCR confirmed mild COVID-19 infection. SARS-CoV-2 D614G and omicron RBD specific B cell subsets in peripheral circulation were assessed by flow cytometry. IgG, IgG3 and IgA antibody titers toward RBD, spike and nucleocapsid antigens in the plasma were evaluated by ELISA.</AbstractText><AbstractText Label="RESULTS">The frequency of the B cells specific to D614G-RBD were comparable in convalescent groups with and without PCC in both males and females. Notably, in females with PCC, the anti-D614G RBD specific double negative (IgD<sup>-</sup>CD27<sup>-</sup>) B cells showed significant correlation with the number of symptoms at acute of infection. Anti-spike antibody responses were also higher at 3 months post-infection in females who developed PCC, but not in the male PCC group. On the other hand, the male PCC group also showed consistently high anti-RBD IgG responses compared to all other groups.</AbstractText><AbstractText Label="CONCLUSIONS">The antibody responses to the spike protein, but not the anti-RBD B cell responses diverge between convalescent males and females who develop PCC. Our findings also suggest that sex-related factors may also be involved in the development of PCC via modulating antibody responses to the SARS-CoV-2 antigens.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Limoges, Quenum, Chowdhury, Rexhepi, Namvarpour, Akbari, Rioux-Perreault, Nandi, Lucier, Lemaire-Paquette, Premkumar, Durocher, Cantin, L&#xe9;vesque, Dionne, Menendez, Ilangumaran, Allard-Chamard, Pich&#xe9; and Ramanathan.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Limoges</LastName><ForeName>Marc-Andr&#xe9;</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Immunology and Cell Biology, Faculty of Medicine and Health Sciences, Sherbrooke, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quenum</LastName><ForeName>Akouavi Julite Irmine</ForeName><Initials>AJI</Initials><AffiliationInfo><Affiliation>Department of Immunology and Cell Biology, Faculty of Medicine and Health Sciences, Sherbrooke, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chowdhury</LastName><ForeName>Mohammad Mobarak Hussain</ForeName><Initials>MMH</Initials><AffiliationInfo><Affiliation>Department of Immunology and Cell Biology, Faculty of Medicine and Health Sciences, Sherbrooke, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rexhepi</LastName><ForeName>Fjolla</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Immunology and Cell Biology, Faculty of Medicine and Health Sciences, Sherbrooke, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Namvarpour</LastName><ForeName>Mozhdeh</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Immunology and Cell Biology, Faculty of Medicine and Health Sciences, Sherbrooke, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akbari</LastName><ForeName>Sara Ali</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Immunology and Cell Biology, Faculty of Medicine and Health Sciences, Sherbrooke, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rioux-Perreault</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Infectious Diseases, Faculty of Medicine and Health Sciences, Sherbrooke, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nandi</LastName><ForeName>Madhuparna</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Immunology and Cell Biology, Faculty of Medicine and Health Sciences, Sherbrooke, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lucier</LastName><ForeName>Jean-Fran&#xe7;ois</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of Biology, Faculty of Science, University of Sherbrooke, Sherbrooke, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemaire-Paquette</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Unit&#xe9; de Recherche Clinique et &#xe9;pid&#xe9;miologique, Centre de Recherche du CHUS, Sherbrooke, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Premkumar</LastName><ForeName>Lakshmanane</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durocher</LastName><ForeName>Yves</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Mammalian Cell Expression, Human Health Therapeutics Research Centre, National Research Council Canada, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cantin</LastName><ForeName>Andr&#xe9;</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Departments of Medicine, Faculty of Medicine and Health Sciences, Sherbrooke, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xe9;vesque</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Infectious Diseases, Faculty of Medicine and Health Sciences, Sherbrooke, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratoire de Microbiologie, CIUSSS de l'Estrie - CHUS, Sherbrooke, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dionne</LastName><ForeName>Isabelle J</ForeName><Initials>IJ</Initials><AffiliationInfo><Affiliation>Faculty of Physical Activity Sciences, University of Sherbrooke, Sherbrooke, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Centre on Aging, Affiliated with CIUSSS de l'Estrie-CHUS, Sherbrooke, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Menendez</LastName><ForeName>Alfredo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Infectious Diseases, Faculty of Medicine and Health Sciences, Sherbrooke, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ilangumaran</LastName><ForeName>Subburaj</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Immunology and Cell Biology, Faculty of Medicine and Health Sciences, Sherbrooke, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allard-Chamard</LastName><ForeName>Hugues</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pich&#xe9;</LastName><ForeName>Alain</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Infectious Diseases, Faculty of Medicine and Health Sciences, Sherbrooke, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramanathan</LastName><ForeName>Sheela</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Immunology and Cell Biology, Faculty of Medicine and Health Sciences, Sherbrooke, QC, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>GA4-177773</GrantID><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">RBD specific B cells</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 infection</Keyword><Keyword MajorTopicYN="N">anti-RBD antibody titer</Keyword><Keyword MajorTopicYN="N">long covid</Keyword><Keyword MajorTopicYN="N">post covid condition (PCC)</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>9</Day><Hour>5</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37809081</ArticleId><ArticleId IdType="pmc">PMC10551145</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1223936</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hickie I, Davenport T, Wakefield D, Vollmer-Conna U, Cameron B, Vernon SD, et al. . Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ (2006) 333:575. doi: 10.1136/bmj.38933.585764.AE</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.38933.585764.AE</ArticleId><ArticleId IdType="pmc">PMC1569956</ArticleId><ArticleId IdType="pubmed">16950834</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark DV, Kibuuka H, Millard M, Wakabi S, Lukwago L, Taylor A, et al. . Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study. Lancet Infect Dis (2015) 15:905&#x2013;12. doi: 10.1016/S1473-3099(15)70152-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(15)70152-0</ArticleId><ArticleId IdType="pubmed">25910637</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong KC, Ng AW, Lee LS, Kaw G, Kwek SK, Leow MK, et al. . Pulmonary function and exercise capacity in survivors of severe acute respiratory syndrome. Eur Respir J (2004) 24:436&#x2013;42. doi: 10.1183/09031936.04.00007104</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.04.00007104</ArticleId><ArticleId IdType="pubmed">15358703</ArticleId></ArticleIdList></Reference><Reference><Citation>Carfi A, Bernabei R, Landi F, Gemelli Against COVID-19 Post-Acute Care Study Group . Persistent symptoms in patients after acute COVID-19. JAMA (2020) 324:603&#x2013;5. doi: 10.1001/jama.2020.12603</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. . Post-acute COVID-19 syndrome. Nat Med (2021) 27:601&#x2013;15. doi: 10.1038/s41591-021-01283-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Sykes DL, Holdsworth L, Jawad N, Gunasekera P, Morice AH, Crooks MG. Post-COVID-19 symptom burden: what is long-COVID and how should we manage it? Lung (2021) 199:113&#x2013;9. doi: 10.1007/s00408-021-00423-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00408-021-00423-z</ArticleId><ArticleId IdType="pmc">PMC7875681</ArticleId><ArticleId IdType="pubmed">33569660</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. . Attributes and predictors of long COVID. Nat Med (2021) 27:626&#x2013;31. doi: 10.1038/s41591-021-01292-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>C.C. Global Burden of Disease Long. Wulf Hanson S, Abbafati C, Aerts JG, Al-Aly Z, Ashbaugh C, et al. . Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA (2022) 328:1604&#x2013;15. doi: 10.1001/jama.2022.18931</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.18931</ArticleId><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallant M, Rioux-Perreault C, Lemaire-Paquette S, Pich&#xe9; A. SARS-CoV-2 infection outcomes associated with the Delta variant: a prospective cohort study. J Assoc Med Microbiol Infect Dis Canada (2022) e20220022. doi:&#xa0;10.3138/jammi-2022-0022</Citation><ArticleIdList><ArticleId IdType="doi">10.3138/jammi-2022-0022</ArticleId><ArticleId IdType="pmc">PMC10052902</ArticleId><ArticleId IdType="pubmed">37008579</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, et al. . Multiple early factors anticipate post-acute COVID-19 sequelae. Cell (2022) 185:881&#x2013;895.e20. doi: 10.1016/j.cell.2022.01.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervia C, Zurbuchen Y, Taeschler P, Ballouz T, Menges D, Hasler S, et al. . Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome. Nat Commun (2022) 13:446. doi: 10.1038/s41467-021-27797-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27797-1</ArticleId><ArticleId IdType="pmc">PMC8789854</ArticleId><ArticleId IdType="pubmed">35078982</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deeks SG. Early clues regarding the pathogenesis of long-COVID. Trends Immunol (2022) 43:268&#x2013;70. doi: 10.1016/j.it.2022.02.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2022.02.008</ArticleId><ArticleId IdType="pmc">PMC8901423</ArticleId><ArticleId IdType="pubmed">35272932</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenks SA, Cashman KS, Zumaquero E, Marigorta UM, Patel AV, Wang X, et al. . Distinct effector B cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus. Immunity (2018) 49:725&#x2013;739.e6. doi: 10.1016/j.immuni.2018.08.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2018.08.015</ArticleId><ArticleId IdType="pmc">PMC6217820</ArticleId><ArticleId IdType="pubmed">30314758</ArticleId></ArticleIdList></Reference><Reference><Citation>Glynne P, Tahmasebi N, Gant V, Gupta R. Long COVID following mild SARS-CoV-2 infection: characteristic T cell alterations and response to antihistamines. J Investig Med (2022) 70:61&#x2013;7. doi: 10.1136/jim-2021-002051</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jim-2021-002051</ArticleId><ArticleId IdType="pmc">PMC8494538</ArticleId><ArticleId IdType="pubmed">34611034</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deitchman AN, Torres L, Iyer NS, Munter SE, Nixon CC, et al. . Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep (2021) 36:109518. doi: 10.1016/j.celrep.2021.109518</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109518</ArticleId><ArticleId IdType="pmc">PMC8342976</ArticleId><ArticleId IdType="pubmed">34358460</ArticleId></ArticleIdList></Reference><Reference><Citation>
WHO  (2021). Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1.</Citation></Reference><Reference><Citation>Cohen KW, Linderman SL, Moodie Z, Czartoski J, Lai L, Mantus G, et al. . Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. Cell Rep Med (2021) 2:100354. doi: 10.1016/j.xcrm.2021.100354</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100354</ArticleId><ArticleId IdType="pmc">PMC8253687</ArticleId><ArticleId IdType="pubmed">34250512</ArticleId></ArticleIdList></Reference><Reference><Citation>Robbiani DF, Gaebler C, Muecksch F, Lorenzi JCC, Wang Z, Cho A, et al. . Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature (2020) 584:437&#x2013;42. doi:&#xa0;10.1038/s41586-020-2456-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2456-9</ArticleId><ArticleId IdType="pmc">PMC7442695</ArticleId><ArticleId IdType="pubmed">32555388</ArticleId></ArticleIdList></Reference><Reference><Citation>Limoges MA, Lortie A, Demontier E, Quenum AJI, Lessard F, Drouin Z, et al. . SARS-cov-2 mRNA vaccine-induced immune responses in rheumatoid arthritis. J Leukoc Biol (2023). doi: 10.1093/jleuko/qiad086</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jleuko/qiad086</ArticleId><ArticleId IdType="pmc">PMC10533224</ArticleId><ArticleId IdType="pubmed">37478373</ArticleId></ArticleIdList></Reference><Reference><Citation>Moura AD, da Costa HHM, Correa VA, de SLAK, Lindoso JAL, De Gaspari E, et al. . Assessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patients. Sci Rep (2021) 11:17642. doi: 10.1038/s41598-021-95045-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95045-z</ArticleId><ArticleId IdType="pmc">PMC8417219</ArticleId><ArticleId IdType="pubmed">34480056</ArticleId></ArticleIdList></Reference><Reference><Citation>Colwill K, Galipeau Y, Stuible M, Gervais C, Arnold C, Rathod B, et al. . A scalable serology solution for profiling humoral immune responses to SARS-CoV-2 infection and vaccination. Clin Transl Immunol (2022) 11:e1380. doi: 10.1002/cti2.1380</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cti2.1380</ArticleId><ArticleId IdType="pmc">PMC8942165</ArticleId><ArticleId IdType="pubmed">35356067</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallant M, Mercier K, Rioux-Perreault C, Lemaire-Paquette S, Pich&#xe9; A. Prevalence of persistent symptoms at least 1 month after SARS-CoV-2 Omicron infection in adults. J Assoc Med Microbiol Infect Dis Canada (2022) 8:57&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10052909</ArticleId><ArticleId IdType="pubmed">37008583</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis RH, Santillana M, Ognyanova K, Safarpour A, Lunz Trujillo K, Simonson MD, et al. . Prevalence and correlates of long COVID symptoms among US adults. JAMA Netw Open (2022) 5:e2238804. doi: 10.1001/jamanetworkopen.2022.38804</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.38804</ArticleId><ArticleId IdType="pmc">PMC9614581</ArticleId><ArticleId IdType="pubmed">36301542</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruschil C, Gabernet G, Lepennetier G, Heumos S, Kaminski M, Hracsko Z, et al. . Specific induction of double negative B cells during protective and pathogenic immune responses. Front Immunol (2020) 11:606338. doi: 10.3389/fimmu.2020.606338</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.606338</ArticleId><ArticleId IdType="pmc">PMC7775384</ArticleId><ArticleId IdType="pubmed">33391273</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckers L, Somers V, Fraussen J. IgD(-)CD27(-) double negative (DN) B cells: origins and functions in health and disease. Immunol Lett (2023) 255:67&#x2013;76. doi: 10.1016/j.imlet.2023.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imlet.2023.03.003</ArticleId><ArticleId IdType="pubmed">36906182</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanz I, Wei C, Jenks SA, Cashman KS, Tipton C, Woodruff MC, et al. . Challenges and opportunities for consistent classification of human B cell and plasma cell populations. Front Immunol (2019) 10:2458. doi: 10.3389/fimmu.2019.02458</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02458</ArticleId><ArticleId IdType="pmc">PMC6813733</ArticleId><ArticleId IdType="pubmed">31681331</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokal A, Chappert P, Barba-Spaeth G, Roeser A, Fourati S, Azzaoui I, et al. . Maturation and persistence of the anti-SARS-CoV-2 memory B cell response. Cell (2021) 184:1201&#x2013;1213.e14. doi: 10.1016/j.cell.2021.01.050</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.01.050</ArticleId><ArticleId IdType="pmc">PMC7994111</ArticleId><ArticleId IdType="pubmed">33571429</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein U, Rajewsky K, Kuppers R. Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J Exp Med (1998) 188:1679&#x2013;89. doi: 10.1084/jem.188.9.1679</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.188.9.1679</ArticleId><ArticleId IdType="pmc">PMC2212515</ArticleId><ArticleId IdType="pubmed">9802980</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneko N, Kuo HH, Boucau J, Farmer JR, Allard-Chamard H, Mahajan VS, et al. . Massachusetts consortium on pathogen readiness specimen working, loss of bcl-6-expressing T follicular helper cells and germinal centers in COVID-19. Cell (2020) 183:143&#x2013;57.e13. doi:&#xa0;10.1016/j.cell.2020.08.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.08.025</ArticleId><ArticleId IdType="pmc">PMC7437499</ArticleId><ArticleId IdType="pubmed">32877699</ArticleId></ArticleIdList></Reference><Reference><Citation>Krause R, Snyman J, Shi-Hsia H, Muema D, Karim F, Ganga Y, et al. . HIV skews the SARS-CoV-2 B cell response towards an extrafollicular maturation pathway. Elife (2022) 11:e79924. doi: 10.7554/eLife.79924</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.79924</ArticleId><ArticleId IdType="pmc">PMC9643005</ArticleId><ArticleId IdType="pubmed">36300787</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff M, Ramonell R, Cashman K, Nguyen D, Ley A, Kyu S, et al. . Critically ill SARS-CoV-2 patients display lupus-like hallmarks of extrafollicular B cell activation. medRxiv (2020). doi:&#xa0;10.1101/2020.04.29.20083717</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.29.20083717</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheatley AK, Juno JA, Wang JJ, Selva KJ, Reynaldi A, Tan HX, et al. . Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nat Commun (2021) 12:1162. doi: 10.1038/s41467-021-21444-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21444-5</ArticleId><ArticleId IdType="pmc">PMC7896046</ArticleId><ArticleId IdType="pubmed">33608522</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawford KHD, Dingens AS, Eguia R, Wolf CR, Wilcox N, Logue JK, et al. . Dynamics of neutralizing antibody titers in the months after severe acute respiratory syndrome coronavirus 2 infection. J Infect Dis (2021) 223:197&#x2013;205. doi: 10.1093/infdis/jiaa618</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa618</ArticleId><ArticleId IdType="pmc">PMC7543487</ArticleId><ArticleId IdType="pubmed">33535236</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaudoin-Bussieres G, Laumaea A, Anand SP, Prevost J, Gasser R, Goyette G, et al. . Decline of humoral responses against SARS-CoV-2 spike in convalescent individuals. mBio (2020) 11:e02590-20. doi: 10.1128/mBio.02590-20</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.02590-20</ArticleId><ArticleId IdType="pmc">PMC7569150</ArticleId><ArticleId IdType="pubmed">33067385</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodda LB, Netland J, Shehata L, Pruner KB, Morawski PA, Thouvenel CD, et al. . Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. Cell (2021) 184:169&#x2013;83.e17. doi:&#xa0;10.1016/j.cell.2020.11.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.11.029</ArticleId><ArticleId IdType="pmc">PMC7682481</ArticleId><ArticleId IdType="pubmed">33296701</ArticleId></ArticleIdList></Reference><Reference><Citation>Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. . Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science (2021) 371:eabf4063. doi: 10.1126/science.abf4063</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf4063</ArticleId><ArticleId IdType="pmc">PMC7919858</ArticleId><ArticleId IdType="pubmed">33408181</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al. . Evolution of antibody immunity to SARS-CoV-2. Nature (2021) 591:639&#x2013;44. doi: 10.1038/s41586-021-03207-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03207-w</ArticleId><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueiredo-Campos P, Blankenhaus B, Mota C, Gomes A, Serrano M, Ariotti S, et al. . Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset. Eur J Immunol (2020) 50:2025&#x2013;40. doi: 10.1002/eji.202048970</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.202048970</ArticleId><ArticleId IdType="pmc">PMC7756220</ArticleId><ArticleId IdType="pubmed">33084029</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan X, Chen G, Jin Z, Zhang Z, Zhang B, He J, et al. . Anti-SARS-CoV-2 IgG levels in relation to disease severity of COVID-19. J Med Virol (2022) 94:380&#x2013;3. doi: 10.1002/jmv.27274</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27274</ArticleId><ArticleId IdType="pmc">PMC8426683</ArticleId><ArticleId IdType="pubmed">34403142</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo H, Jia T, Chen J, Zeng S, Qiu Z, Wu S, et al. . The characterization of disease severity associated igG subclasses response in COVID-19 patients. Front Immunol (2021) 12:632814. doi: 10.3389/fimmu.2021.632814</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.632814</ArticleId><ArticleId IdType="pmc">PMC7982848</ArticleId><ArticleId IdType="pubmed">33763078</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho MS, Chen WJ, Chen HY, Lin SF, Wang MC, Di J, et al. . Neutralizing antibody response and SARS severity. Emerg Infect Dis (2005) 11:1730&#x2013;7. doi: 10.3201/eid1111.040659</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1111.040659</ArticleId><ArticleId IdType="pmc">PMC3367364</ArticleId><ArticleId IdType="pubmed">16318725</ArticleId></ArticleIdList></Reference><Reference><Citation>Alshukairi AN, Khalid I, Ahmed WA, Dada AM, Bayumi DT, Malic LS, et al. . Antibody response and disease severity in healthcare worker MERS survivors. Emerg Infect Dis 22 (2016). doi: 10.3201/eid2206.160010</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2206.160010</ArticleId><ArticleId IdType="pmc">PMC4880093</ArticleId><ArticleId IdType="pubmed">27192543</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeshita M, Nishina N, Moriyama S, Takahashi Y, Uwamino Y, Nagata M, et al. . Incomplete humoral response including neutralizing antibodies in asymptomatic to mild COVID-19 patients in Japan. Virology (2021) 555:35&#x2013;43. doi: 10.1016/j.virol.2020.12.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2020.12.020</ArticleId><ArticleId IdType="pmc">PMC7787511</ArticleId><ArticleId IdType="pubmed">33450669</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazor-Blanchet C, Zygoura P, Dafni U, Lamoth F, Tsourti Z, Lobritz MA, et al. . Low neutralizing antibody titers after asymptomatic or non-severe SARS-CoV-2 infection over a 6-month assessment period. J Infect (2022) 84:722&#x2013;46. doi: 10.1016/j.jinf.2022.02.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2022.02.001</ArticleId><ArticleId IdType="pmc">PMC8817763</ArticleId><ArticleId IdType="pubmed">35134464</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau EHY, Tsang OTY, Hui DSC, Kwan MYW, Chan WH, Chiu SS, et al. . Neutralizing antibody titres in SARS-CoV-2 infections. Nat Commun (2021) 12:63. doi: 10.1038/s41467-020-20247-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-20247-4</ArticleId><ArticleId IdType="pmc">PMC7782739</ArticleId><ArticleId IdType="pubmed">33397909</ArticleId></ArticleIdList></Reference><Reference><Citation>Breuer A, Raphael A, Stern H, Odeh M, Fiszlinski J, Algur N, et al. . SARS-CoV-2 antibodies started to decline just four months after COVID-19 infection in a paediatric population. Acta Paediatr (2021) 110:3054&#x2013;62. doi: 10.1111/apa.16031</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apa.16031</ArticleId><ArticleId IdType="pmc">PMC8444680</ArticleId><ArticleId IdType="pubmed">34265136</ArticleId></ArticleIdList></Reference><Reference><Citation>Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. . Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med (2020) 71:2027&#x2013;34. doi:&#xa0;10.1093/cid/ciaa344</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa344</ArticleId><ArticleId IdType="pubmed">32350462</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel MM, Thornburg NJ, Stubblefield WB, Talbot HK, Coughlin MM, Feldstein LR, et al. . Change in antibodies to SARS-CoV-2 over 60 days among health care personnel in nashville, tennessee. JAMA (2020) 324:1781&#x2013;2. doi: 10.1001/jama.2020.18796</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.18796</ArticleId><ArticleId IdType="pmc">PMC7499233</ArticleId><ArticleId IdType="pubmed">32940635</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et al. . Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild covid-19. N Engl J Med (2020) 383:1085&#x2013;7. doi: 10.1056/NEJMc2025179</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2025179</ArticleId><ArticleId IdType="pmc">PMC7397184</ArticleId><ArticleId IdType="pubmed">32706954</ArticleId></ArticleIdList></Reference><Reference><Citation>Horton DB, Barrett ES, Roy J, Gennaro ML, Andrews T, Greenberg P, et al. . Determinants and dynamics of SARS-CoV-2 infection in a diverse population: 6-month evaluation of a prospective cohort study. J Infect Dis (2021) 224:1345&#x2013;56. doi: 10.1093/infdis/jiab411</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab411</ArticleId><ArticleId IdType="pmc">PMC8436370</ArticleId><ArticleId IdType="pubmed">34387310</ArticleId></ArticleIdList></Reference><Reference><Citation>Fjelltveit EB, Blomberg B, Kuwelker K, Zhou F, Onyango TB, Brokstad KA, et al. . Symptom burden and immune dynamics 6 to 18 months following mild severe acute respiratory syndrome coronavirus 2 infection (SARS-CoV-2): a case-control study. Clin Infect Dis (2023) 76:e60&#x2013;70. doi: 10.1093/cid/ciac655</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac655</ArticleId><ArticleId IdType="pmc">PMC9384725</ArticleId><ArticleId IdType="pubmed">35959897</ArticleId></ArticleIdList></Reference><Reference><Citation>Paavonen T, Andersson LC, Adlercreutz H. Sex hormone regulation of in vitro immune response. Estradiol enhances human B cell maturation via inhibition of suppressor T cells in pokeweed mitogen-stimulated cultures. J Exp Med (1981) 154:1935&#x2013;45. doi: 10.1084/jem.154.6.1935</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.154.6.1935</ArticleId><ArticleId IdType="pmc">PMC2186551</ArticleId><ArticleId IdType="pubmed">6459399</ArticleId></ArticleIdList></Reference><Reference><Citation>Sthoeger ZM, Chiorazzi N, Lahita RG. Regulation of the immune response by sex hormones. I. In vitro effects of estradiol and testosterone on pokeweed mitogen-induced human B cell differentiation. J Immunol (1988) 141:91&#x2013;8. doi: 10.4049/jimmunol.141.1.91</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.141.1.91</ArticleId><ArticleId IdType="pubmed">3288699</ArticleId></ArticleIdList></Reference><Reference><Citation>Grzelak L, Velay A, Madec Y, Gallais F, Staropoli I, Schmidt-Mutter C, et al. . Sex differences in the evolution of neutralizing antibodies to severe acute respiratory syndrome coronavirus 2. J Infect Dis (2021) 224:983&#x2013;8. doi: 10.1093/infdis/jiab127</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab127</ArticleId><ArticleId IdType="pmc">PMC7989436</ArticleId><ArticleId IdType="pubmed">33693749</ArticleId></ArticleIdList></Reference><Reference><Citation>Falagas ME, Mourtzoukou EG, Vardakas KZ. Sex differences in the incidence and severity of respiratory tract infections. Respir Med (2007) 101:1845&#x2013;63. doi: 10.1016/j.rmed.2007.04.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2007.04.011</ArticleId><ArticleId IdType="pubmed">17544265</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell LA, Zhang T, Tingle AJ. Differential antibody responses to rubella virus infection in males and females. J Infect Dis (1992) 166:1258&#x2013;65. doi: 10.1093/infdis/166.6.1258</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/166.6.1258</ArticleId><ArticleId IdType="pubmed">1431244</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozgocer T, Dagli SN, Ceylan MR, Disli F, Ucar C, Yildiz S. Analysis of long-term antibody response in COVID-19 patients by symptoms grade, gender, age, BMI, and medication. J Med Virol (2022) 94:1412&#x2013;8. doi: 10.1002/jmv.27452</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27452</ArticleId><ArticleId IdType="pmc">PMC8662095</ArticleId><ArticleId IdType="pubmed">34766646</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai B, Clarke K, Bauer DL, Moehling Geffel KK, Kupul S, Schratz LJ, et al. . SARS-coV-2 antibody response is associated with age and body mass index in convalescent outpatients. J Immunol (2022) 208:1711&#x2013;8. doi: 10.4049/jimmunol.2101156</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2101156</ArticleId><ArticleId IdType="pmc">PMC8976825</ArticleId><ArticleId IdType="pubmed">35321882</ArticleId></ArticleIdList></Reference><Reference><Citation>Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, et al. . Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun (2020) 11:6317. doi: 10.1038/s41467-020-19741-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19741-6</ArticleId><ArticleId IdType="pmc">PMC7726563</ArticleId><ArticleId IdType="pubmed">33298944</ArticleId></ArticleIdList></Reference><Reference><Citation>Serfling RE, Sherman IL, Houseworth WJ. Excess pneumonia-influenza mortality by age and sex in three major influenza A2 epidemics, United States, 1957-58, 1960 and 1963. Am J Epidemiol (1967) 86:433&#x2013;41. doi: 10.1093/oxfordjournals.aje.a120753</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.aje.a120753</ArticleId><ArticleId IdType="pubmed">6058395</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilbourne ED. Influenza pandemics of the 20th century. Emerg Infect Dis (2006) 12:9&#x2013;14. doi: 10.3201/eid1201.051254</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1201.051254</ArticleId><ArticleId IdType="pmc">PMC3291411</ArticleId><ArticleId IdType="pubmed">16494710</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan R, Klein SL. The intersection of sex and gender in the treatment of influenza. Curr Opin Virol (2019) 35:35&#x2013;41. doi: 10.1016/j.coviro.2019.02.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2019.02.009</ArticleId><ArticleId IdType="pmc">PMC6556398</ArticleId><ArticleId IdType="pubmed">30901632</ArticleId></ArticleIdList></Reference><Reference><Citation>Regis E, Fontanella S, Lin L, Howard R, Haider S, Curtin JA, et al. . Sex differences in innate anti-viral immune responses to respiratory viruses and in their clinical outcomes in a birth cohort study. Sci Rep (2021) 11:23741. doi: 10.1038/s41598-021-03044-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-03044-x</ArticleId><ArticleId IdType="pmc">PMC8660814</ArticleId><ArticleId IdType="pubmed">34887467</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovats S. Estrogen receptors regulate innate immune cells and signaling pathways. Cell Immunol (2015) 294:63&#x2013;9. doi: 10.1016/j.cellimm.2015.01.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellimm.2015.01.018</ArticleId><ArticleId IdType="pmc">PMC4380804</ArticleId><ArticleId IdType="pubmed">25682174</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischinger S, Boudreau CM, Butler AL, Streeck H, Alter G. Sex differences in vaccine-induced humoral immunity. Semin Immunopathol (2019) 41:239&#x2013;49. doi: 10.1007/s00281-018-0726-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-018-0726-5</ArticleId><ArticleId IdType="pmc">PMC6373179</ArticleId><ArticleId IdType="pubmed">30547182</ArticleId></ArticleIdList></Reference><Reference><Citation>Demonbreun AR, Sancilio A, Velez ME, Ryan DT, Pesce L, Saber R, et al. . COVID-19 mRNA vaccination generates greater immunoglobulin G levels in women compared to men. J Infect Dis (2021) 224:793&#x2013;7. doi: 10.1093/infdis/jiab314</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab314</ArticleId><ArticleId IdType="pmc">PMC8536925</ArticleId><ArticleId IdType="pubmed">34117873</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebinger JE, Joung S, Liu Y, Wu M, Weber B, Claggett B, et al. . Demographic and clinical characteristics associated with variations in antibody response to BNT162b2 COVID-19 vaccination among healthcare workers at an academic medical centre: a longitudinal cohort analysis. BMJ Open (2022) 12:e059994. doi: 10.1136/bmjopen-2021-059994</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-059994</ArticleId><ArticleId IdType="pmc">PMC9130668</ArticleId><ArticleId IdType="pubmed">35613792</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey M, Barker CI, Snape MD, Kelly DF, Truck J, Pollard AJ. Sex-dependent immune responses to infant vaccination: an individual participant data meta-analysis of antibody and memory B cells. Vaccine (2016) 34:1657&#x2013;64. doi: 10.1016/j.vaccine.2016.02.036</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.02.036</ArticleId><ArticleId IdType="pubmed">26920472</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster SE, Tsuji NL, Clemente MJ, Holodick NE. Age-related changes in antigen-specific natural antibodies are influenced by sex. Front Immunol (2022) 13:1047297. doi: 10.3389/fimmu.2022.1047297</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1047297</ArticleId><ArticleId IdType="pmc">PMC9878317</ArticleId><ArticleId IdType="pubmed">36713434</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohm M, Boef AGC, Stoof SP, van Ravenhorst MB, van der Klis FRM, Berbers GAM, et al. . Sex-related differences in the immune response to meningococcal vaccinations during adolescence. Front Public Health (2022) 10:871670. doi: 10.3389/fpubh.2022.871670</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.871670</ArticleId><ArticleId IdType="pmc">PMC9120633</ArticleId><ArticleId IdType="pubmed">35602158</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol (2016) 16:626&#x2013;38. doi: 10.1038/nri.2016.90</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2016.90</ArticleId><ArticleId IdType="pubmed">27546235</ArticleId></ArticleIdList></Reference><Reference><Citation>Capelle CM, Cire S, Domingues O, Ernens I, Hedin F, Fischer A, et al. . Combinatorial analysis reveals highly coordinated early-stage immune reactions that predict later antiviral immunity in mild COVID-19 patients. Cell Rep Med (2022) 3:100600. doi: 10.1016/j.xcrm.2022.100600</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100600</ArticleId><ArticleId IdType="pmc">PMC8960124</ArticleId><ArticleId IdType="pubmed">35480624</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparks R, Lau WW, Liu C, Han KL, Vrindten KL, Sun G, et al. . Influenza vaccination reveals sex dimorphic imprints of prior mild COVID-19. Nature (2023) 614:752&#x2013;61. doi: 10.1038/s41586-022-05670-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05670-5</ArticleId><ArticleId IdType="pmc">PMC10481789</ArticleId><ArticleId IdType="pubmed">36599369</ArticleId></ArticleIdList></Reference><Reference><Citation>Mifsud NA, Purcell AW, Chen W, Holdsworth R, Tait BD, McCluskey J. Immunodominance hierarchies and gender bias in direct T(CD8)-cell alloreactivity. Am J Transplant (2008) 8:121&#x2013;32. doi: 10.1111/j.1600-6143.2007.02044.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-6143.2007.02044.x</ArticleId><ArticleId IdType="pubmed">18093278</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Castelli FA, Zhu X, Wu M, Maillere B, BenMohamed L. Gender-dependent HLA-DR-restricted epitopes identified from herpes simplex virus type 1 glycoprotein D. Clin Vaccine Immunol (2008) 15:1436&#x2013;49. doi: 10.1128/CVI.00123-08</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00123-08</ArticleId><ArticleId IdType="pmc">PMC2546687</ArticleId><ArticleId IdType="pubmed">18667634</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu C, Cheng S, Chen K, Song Q, Liu C, Fan C, et al. . Sex differences in genomic features of hepatitis B-associated hepatocellular carcinoma with distinct antitumor immunity. Cell Mol Gastroenterol Hepatol (2023) 15:327&#x2013;54. doi: 10.1016/j.jcmgh.2022.10.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmgh.2022.10.009</ArticleId><ArticleId IdType="pmc">PMC9772570</ArticleId><ArticleId IdType="pubmed">36272708</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C, Jin J, Yang Y, Sun H, Wu L, Shen M, et al. . Androgen receptor-mediated CD8(+) T cell stemness programs drive sex differences in antitumor immunity. Immunity (2022) 55:1268&#x2013;1283 e9. doi: 10.1016/j.immuni.2022.05.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2022.05.012</ArticleId><ArticleId IdType="pubmed">35700739</ArticleId></ArticleIdList></Reference><Reference><Citation>Nayrac M, Dube M, Sannier G, Nicolas A, Marchitto L, Tastet O, et al. . Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen. Cell Rep (2022) 39:111013. doi: 10.1016/j.celrep.2022.111013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.111013</ArticleId><ArticleId IdType="pmc">PMC9189142</ArticleId><ArticleId IdType="pubmed">35732172</ArticleId></ArticleIdList></Reference><Reference><Citation>Elsner RA, Shlomchik MJ. Germinal center and extrafollicular B cell responses in vaccination, immunity, and autoimmunity. Immunity (2020) 53:1136&#x2013;50. doi: 10.1016/j.immuni.2020.11.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.11.006</ArticleId><ArticleId IdType="pmc">PMC7748291</ArticleId><ArticleId IdType="pubmed">33326765</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijay R, Guthmiller JJ, Sturtz AJ, Surette FA, Rogers KJ, Sompallae RR, et al. . Infection-induced plasmablasts are a nutrient sink that impairs humoral immunity to malaria. Nat Immunol (2020) 21:790&#x2013;801. doi: 10.1038/s41590-020-0678-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-0678-5</ArticleId><ArticleId IdType="pmc">PMC7316608</ArticleId><ArticleId IdType="pubmed">32424361</ArticleId></ArticleIdList></Reference><Reference><Citation>Castleman MJ, Stumpf MM, Therrien NR, Smith MJ, Lesteberg KE, Palmer BE, et al. . Autoantibodies elicited with SARS-CoV-2 infection are linked to alterations in double negative B cells. Front Immunol (2022) 13:988125. doi: 10.3389/fimmu.2022.988125</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.988125</ArticleId><ArticleId IdType="pmc">PMC9484582</ArticleId><ArticleId IdType="pubmed">36131937</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira C, Harris BHL, Di Giovannantonio M, Rosadas C, Short CE, Quinlan R, et al. . Antibody response to SARS-CoV-2 infection is not associated with Post-COVID-19 Syndrome in healthcare workers. J Infect Dis (2021) 223:1671&#x2013;6. doi: 10.1093/infdis/jiab120</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab120</ArticleId><ArticleId IdType="pmc">PMC7989400</ArticleId><ArticleId IdType="pubmed">33675366</ArticleId></ArticleIdList></Reference><Reference><Citation>Joung S, Weber B, Wu M, Liu Y, Tang AB, Driver M, et al. . Serological response to vaccination in post-acute sequelae of COVID. BMC Infect Dis (2023) 23:97. doi: 10.1186/s12879-023-08060-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-023-08060-y</ArticleId><ArticleId IdType="pmc">PMC9933819</ArticleId><ArticleId IdType="pubmed">36797666</ArticleId></ArticleIdList></Reference><Reference><Citation>Santa Cruz A, Mendes-Frias A, Azarias-da-Silva M, Andre S, Oliveira AI, Pires O, et al. . Post-acute sequelae of COVID-19 is characterized by diminished peripheral CD8(+)beta7 integrin(+) T cells and anti-SARS-CoV-2 IgA response. Nat Commun (2023) 14:1772. doi: 10.1038/s41467-023-37368-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-37368-1</ArticleId><ArticleId IdType="pmc">PMC10061413</ArticleId><ArticleId IdType="pubmed">36997530</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Lu S, Tang AF, Durstenfeld MS, Ho HE, Goldberg SA, et al. . Markers of immune activation and inflammation in individuals with postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. J Infect Dis (2021) 224:1839&#x2013;48. doi: 10.1093/infdis/jiab490</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab490</ArticleId><ArticleId IdType="pmc">PMC8643408</ArticleId><ArticleId IdType="pubmed">34677601</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol (2019) 17:181&#x2013;92. doi: 10.1038/s41579-018-0118-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-018-0118-9</ArticleId><ArticleId IdType="pmc">PMC7097006</ArticleId><ArticleId IdType="pubmed">30531947</ArticleId></ArticleIdList></Reference><Reference><Citation>Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe (2021) 2:e13&#x2013;22. doi: 10.1016/S2666-5247(20)30172-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(20)30172-5</ArticleId><ArticleId IdType="pmc">PMC7837230</ArticleId><ArticleId IdType="pubmed">33521734</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan D, Sze S, Abraham S, Williams CM, Tang JW, Barer MR, et al. . Rapid tests for quantification of infectiousness are urgently required in patients with COVID-19. Lancet Microbe (2021) 2:e286&#x2013;7. doi: 10.1016/S2666-5247(21)00089-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(21)00089-6</ArticleId><ArticleId IdType="pmc">PMC8115941</ArticleId><ArticleId IdType="pubmed">34002171</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank Z, Senussi Y, Manickas-Hill Z, Yu XG, Li JZ, Alter G, et al. . Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae. Clin Infect Dis (2022) 76:e487&#x2013;90. doi: 10.1101/2022.06.14.22276401</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.06.14.22276401</ArticleId><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Tejerina F, Catalan P, Rodriguez-Grande C, Adan J, Rodriguez-Gonzalez C, Munoz P, et al. . Post-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID-19. BMC Infect Dis (2022) 22:211. doi: 10.1186/s12879-022-07153-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07153-4</ArticleId><ArticleId IdType="pmc">PMC8892394</ArticleId><ArticleId IdType="pubmed">35240997</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein SR, Ramelli SC, Grazioli A, Chung JY, Singh M, Yinda CK, et al. . SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature (2022) 612:758&#x2013;63. doi: 10.1038/s41586-022-05542-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05542-y</ArticleId><ArticleId IdType="pmc">PMC9749650</ArticleId><ArticleId IdType="pubmed">36517603</ArticleId></ArticleIdList></Reference><Reference><Citation>Junqueira C, Crespo A, Ranjbar S, de Lacerda LB, Lewandrowski M, Ingber J, et al. . FcgammaR-mediated SARS-CoV-2 infection of monocytes activates inflammation. Nature (2022) 606:576&#x2013;84. doi: 10.1038/s41586-022-04702-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04702-4</ArticleId><ArticleId IdType="pmc">PMC10071495</ArticleId><ArticleId IdType="pubmed">35385861</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol (2004) 203:631&#x2013;7. doi: 10.1002/path.1570</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.1570</ArticleId><ArticleId IdType="pmc">PMC7167720</ArticleId><ArticleId IdType="pubmed">15141377</ArticleId></ArticleIdList></Reference><Reference><Citation>Puelles VG, Lutgehetmann M, Lindenmeyer MT, Sperhake JP, Wong MN, Allweiss L, et al. . Multiorgan and renal tropism of SARS-cov-2. N Engl J Med (2020) 383:590&#x2013;2. doi: 10.1056/NEJMc2011400</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2011400</ArticleId><ArticleId IdType="pmc">PMC7240771</ArticleId><ArticleId IdType="pubmed">32402155</ArticleId></ArticleIdList></Reference><Reference><Citation>Callow KA, Parry HF, Sergeant M, Tyrrell DA. The time course of the immune response to experimental coronavirus infection of man. Epidemiol Infect (1990) 105:435&#x2013;46. doi: 10.1017/S0950268800048019</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268800048019</ArticleId><ArticleId IdType="pmc">PMC2271881</ArticleId><ArticleId IdType="pubmed">2170159</ArticleId></ArticleIdList></Reference><Reference><Citation>Woldemeskel BA, Kwaa AK, Garliss CC, Laeyendecker O, Ray SC, Blankson JN. Healthy donor T cell responses to common cold coronaviruses and SARS-CoV-2. J Clin Invest (2020) 130:6631&#x2013;8. doi: 10.1172/JCI143120</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI143120</ArticleId><ArticleId IdType="pmc">PMC7685719</ArticleId><ArticleId IdType="pubmed">32966269</ArticleId></ArticleIdList></Reference><Reference><Citation>Diez-Cirarda M, Yus M, Gomez-Ruiz N, Polidura C, Gil-Martinez L, Delgado-Alonso C, et al. . Multimodal neuroimaging in post-COVID syndrome and correlation with cognition. Brain Awac (2022) 384. doi:&#xa0;10.1093/brain/awac384</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac384</ArticleId><ArticleId IdType="pmc">PMC9620345</ArticleId><ArticleId IdType="pubmed">36288544</ArticleId></ArticleIdList></Reference><Reference><Citation>Guedj E, Campion JY, Dudouet P, Kaphan E, Bregeon F, Tissot-Dupont H, et al. . (18)F-FDG brain PET hypometabolism in patients with long COVID. Eur J Nucl Med Mol Imaging (2021) 48:2823&#x2013;33. doi: 10.1007/s00259-021-05215-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-021-05215-4</ArticleId><ArticleId IdType="pmc">PMC7837643</ArticleId><ArticleId IdType="pubmed">33501506</ArticleId></ArticleIdList></Reference><Reference><Citation>Sollini M, Morbelli S, Ciccarelli M, Cecconi M, Aghemo A, Morelli P, et al. . Long COVID hallmarks on [18F]FDG-PET/CT: a case-control study. Eur J Nucl Med Mol Imaging (2021) 48:3187&#x2013;97. doi: 10.1007/s00259-021-05294-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-021-05294-3</ArticleId><ArticleId IdType="pmc">PMC7937050</ArticleId><ArticleId IdType="pubmed">33677642</ArticleId></ArticleIdList></Reference><Reference><Citation>Guedj E, Million M, Dudouet P, Tissot-Dupont H, Bregeon F, Cammilleri S, et al. . (18)F-FDG brain PET hypometabolism in post-SARS-CoV-2 infection: substrate for persistent/delayed disorders? Eur J Nucl Med Mol Imag (2021) 48:592&#x2013;5. doi: 10.1007/s00259-020-04973-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-020-04973-x</ArticleId><ArticleId IdType="pmc">PMC7391029</ArticleId><ArticleId IdType="pubmed">32728799</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban F, Kulzhabayeva D, Rodrigues NB, Di Vincenzo JD, Gill H, Subramaniapillai M, et al. . COVID-19 vaccination for the prevention and treatment of long COVID: A systematic review and meta-analysis. Brain Behav Immun (2023) 111:211&#x2013;29. doi: 10.1016/j.bbi.2023.03.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2023.03.022</ArticleId><ArticleId IdType="pmc">PMC10067136</ArticleId><ArticleId IdType="pubmed">36990297</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe A, Iwagami M, Yasuhara J, Takagi H, Kuno T. Protective effect of COVID-19 vaccination against long COVID syndrome: a systematic review and meta-analysis. Vaccine (2023) 41:1783&#x2013;90. doi: 10.1016/j.vaccine.2023.02.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.02.008</ArticleId><ArticleId IdType="pmc">PMC9905096</ArticleId><ArticleId IdType="pubmed">36774332</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrahi B, Sudry T, Flaks-Manov N, Yehezkelli Y, Kalkstein N, Akiva P, et al. . Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. BMJ (2023) 380:e072529. doi: 10.1136/bmj-2022-072529</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-072529</ArticleId><ArticleId IdType="pmc">PMC9832503</ArticleId><ArticleId IdType="pubmed">36631153</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>